BIOT Stock Overview
Provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for BIOT from our risk checks.
Biotage AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 185.30 |
| 52 Week High | SEK 197.90 |
| 52 Week Low | SEK 83.05 |
| Beta | 0.83 |
| 11 Month Change | 14.31% |
| 3 Month Change | 15.81% |
| 1 Year Change | 38.80% |
| 33 Year Change | -19.99% |
| 5 Year Change | 68.30% |
| Change since IPO | 81.67% |
Recent News & Updates
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
Jul 19
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Jun 08Recent updates
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
Jul 19Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Jun 08Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?
May 21Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Apr 28Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Apr 17Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Apr 08Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Apr 03Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Mar 04Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
Feb 22Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Feb 21Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 18Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Feb 08Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
Jan 07At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
Dec 08Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Oct 27Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Jul 12An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Jun 08Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
May 24Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 05These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
Mar 12Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Feb 21Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?
Jan 06Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly
Dec 03Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?
Oct 27Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)
Oct 07Biotage (STO:BIOT) Could Easily Take On More Debt
Sep 03Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?
Jul 10A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)
Jun 25Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?
May 28Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 23Biotage (STO:BIOT) Is Paying Out A Larger Dividend Than Last Year
Mar 29Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
Mar 14Is It Time To Consider Buying Biotage AB (publ) (STO:BIOT)?
Feb 28Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Feb 13Shareholder Returns
| BIOT | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 6.6% | 5.3% | -1.8% |
| 1Y | 38.8% | 50.9% | 14.4% |
Return vs Industry: BIOT underperformed the Swedish Life Sciences industry which returned 50.9% over the past year.
Return vs Market: BIOT exceeded the Swedish Market which returned 14.4% over the past year.
Price Volatility
| BIOT volatility | |
|---|---|
| BIOT Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.6% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: BIOT has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 667 | Torben Jorgensen | www.biotage.com |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage AB (publ) Fundamentals Summary
| BIOT fundamental statistics | |
|---|---|
| Market cap | SEK 14.83b |
| Earnings (TTM) | SEK 251.00m |
| Revenue (TTM) | SEK 2.08b |
59.1x
P/E Ratio7.1x
P/S RatioIs BIOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOT income statement (TTM) | |
|---|---|
| Revenue | SEK 2.08b |
| Cost of Revenue | SEK 774.00m |
| Gross Profit | SEK 1.30b |
| Other Expenses | SEK 1.05b |
| Earnings | SEK 251.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 3.14 |
| Gross Margin | 62.73% |
| Net Profit Margin | 12.08% |
| Debt/Equity Ratio | 4.0% |
How did BIOT perform over the long term?
See historical performance and comparison